Загрузка...
Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
Although rituximab, a chimeric monoclonal antibody that specifically binds to CD20, has significantly improved the prognosis for diffuse large B cell lymphoma (DLBCL), one‐third of DLBCL patients demonstrate resistance to rituximab or relapse after rituximab treatment. Thus, a novel approach to ritu...
Сохранить в:
| Опубликовано в: : | Cancer Sci |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970836/ https://ncbi.nlm.nih.gov/pubmed/26920337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12918 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|